Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales [ROS] (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted Return on Sales [ROS] of -44460.56% for Q2 2026, up 97895.44 percentage points from -142356.00% a year earlier and up 37928.80 percentage points from the prior quarter.
Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales [ROS] (2013 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at Viridian Therapeutics, Inc.\DE was -569.68%, up 121261.46 percentage points year-over-year; for FY2025, it was -512.91%, up 98505.30 percentage points from FY2024.
- Annual Return on Sales [ROS] shows a five-year change of +9999.47 percentage points (FY2020 to FY2025).
- In prior years, Viridian Therapeutics, Inc.\DE's Return on Sales [ROS] was -99018.21% in FY2024 (-17983.18 pp), -81035.03% in FY2023 (-73455.80 pp), -7579.23% in FY2022 (-4888.45 pp) and -2690.79% in FY2021 (+7821.59 pp).
- Quarterly Return on Sales [ROS] has run from a low of -142356.00% in Q2 2025 to a high of -56.70% in Q3 2025 over five years.
- On a year-over-year basis, Return on Sales [ROS] has increased in each of the last four quarters, with an average year-over-year change of +16051.95 percentage points over the last eight quarters.
- The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q4 2021, with a gain of 154184.82 percentage points; the weakest was Q2 2023, with a drop of 70777.95 percentage points.
- According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -82389.36% (Q1 2026), -92991.67% (Q4 2025) and -56.70% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.20 Bn | 2.20 Bn | - | -44,460.56% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44,460.56% |
| Mar 31, 2026 | -82,389.36% |
| Dec 31, 2025 | -92,991.67% |
| Sep 30, 2025 | -56.70% |
| Jun 30, 2025 | -142,356.00% |
| Mar 31, 2025 | -130,369.44% |
| Dec 31, 2024 | -121,488.89% |
| Sep 30, 2024 | -97,069.77% |
| Jun 30, 2024 | -100,259.72% |
| Mar 31, 2024 | -77,634.72% |
| Dec 31, 2023 | -99,275.00% |
| Sep 30, 2023 | -71,144.44% |
| Jun 30, 2023 | -82,326.39% |
| Mar 31, 2023 | -73,952.04% |
| Dec 31, 2022 | -46,729.52% |
| Sep 30, 2022 | -2,492.47% |
| Jun 30, 2022 | -11,548.44% |
| Mar 31, 2022 | -11,985.65% |
| Dec 31, 2021 | -13,589.25% |
| Sep 30, 2021 | -6,795.19% |
Viridian Therapeutics, Inc.\DE Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=VRDN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "VRDN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=VRDN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();